You are about to leave Risk Strategies website and view the content of an external website.
You are leaving risk-strategies.com
By accessing this link, you will be leaving Risk Strategies website and entering a website hosted by another party. Please be advised that you will no longer be subject to, or under the protection of, the privacy and security policies of Risk Strategies website. We encourage you to read and evaluate the privacy and security policies of the site you are entering, which may be different than those of Risk Strategies.
Summary: In what is likely to become a bellwether development for health plan fiduciary litigation, a new class action lawsuit was recently filed against Johnson & Johnson (J&J), alleging breach of fiduciary duty under the Employee Retirement Income Security Act of 1974 (ERISA) for mismanagement of its pharmacy benefits plan, resulting in millions of dollars overspent by the plan and plan participants.
Read on for more information and next steps for employer plan sponsor fiduciaries.
The J&J class action lawsuit was filed on February 5, 2024 in federal court in New Jersey. The complaint is a dense 74 pages with a slew of allegations against J&J. The suit lists the defendants as J&J in its capacity as an employer plan sponsor fiduciary, J&J’s Pension & Benefits Committee (Committee), as well several members of the Committee, in their individual capacities as plan fiduciaries. As a reminder, fiduciary liability under ERISA §409 can include personal liability to restore losses caused to the plan.
Turning to the complaint allegations, the plaintiffs principally allege “mismanagement of prescription drug benefits,” resulting in millions of dollars overspent by the pharmacy benefit plan. As a result, the plan was required to pay what is purported to be unreasonably more in prescription drug prices, particularly for generic drugs, than it would have paid had it properly managed the plan as ERISA fiduciaries.
Highlights of the plaintiffs’ ERISA breach of fiduciary duty allegations include:
The complaint contains numerous examples regarding the allegations that the J&J plan overpaid for prescription drugs, particularly generic prescription drugs. One example referenced the plan paying over $10,000 for a 90-pill generic drug to treat multiple sclerosis that can be obtained without using insurance at various online and retail pharmacies for between approximately $28 and $77.
As for the J&J plan participants, the complaint alleges they were subject to higher premiums, cost-sharing amounts (including higher deductibles, copayments, and coinsurance), and even lower wages, as a result of J&J’s breach of fiduciary duty.
The underlying duties of care and integrity imposed on fiduciaries are heightened based on the common law of trusts. Congress intended to incorporate these principles of heightened duties on employee benefit plan fiduciaries when it enacted ERISA in 1974.
Accordingly, the fundamental ERISA fiduciary duties are set forth in ERISA §404 and require plan fiduciaries to:
The allegations against J&J and the other named defendants serve as a potent reminder to ERISA plan fiduciaries that the selection and continual monitoring of plan service providers, including third-party administrators (TPAs) and PBMs, is a paramount plan fiduciary obligation.
Moreover, plan fiduciaries must ensure that plan fees and expenses are reasonable, necessary for the plan’s operation, and not excessive for the services provided. Monitoring plan fees and expenses for reasonableness in light of the services provided generally entails a facts and circumstances analysis. However, this does not mean that plans are necessarily required to select the lowest cost service providers in all circumstances[2], as the plaintiffs allege against the J&J plan.
Until this J&J lawsuit was filed in early February, the general trend around health plan fiduciary litigation involved employer health plan sponsors suing their TPAs for breach of ERISA fiduciary duties alleging improper handling of claims payments, failure to provide claims data, cross-plan offsetting, and other related allegations. Recent health plan transparency legislation and regulatory rules serve as catalysts for these particular lawsuits, including the recent Kraft Heinz v. Aetna suit that was voluntarily dropped by Kraft Heinz in December 2023.
The J&J suit appears to be the first of its kind on the health plan fiduciary side. It somewhat mirrors the playbook of ERISA retirement plan fiduciary breach class actions. In these cases, which have been occurring for well over a decade now, employees file class action lawsuits against their employer retirement plan sponsors for excessive fees and imprudent monitoring of plan service providers.
As we previously noted, this recent J&J lawsuit is likely a harbinger of a new trend of health plan fiduciary ligation. Since the lawsuit was just filed in early February, it is too early to speculate on the outcome or even the next steps in the litigation process here.
Nonetheless, plan sponsor fiduciaries are advised to consider, in close collaboration with their legal counsel and benefits consultants, the following action items to bolster protective measures and mitigate potential liability:
Click here for a Department of Labor (DOL) booklet providing more detailed information regarding fiduciary responsibilities under a group health plan.
Risk Strategies is closely watching this lawsuit and will provide updates when available. Reach out to your Risk Strategies team members with any questions or contact us directly at benefits@risk-strategies.com.
[1] This particular allegation is unusual since the J&J plan is funded by a trust, whereas the vast majority of health plans are not. The existence of the trust in this case appears to add a more direct element to a breach of fiduciary duty claim with respect to plan assets since all funds within a plan trust are deemed plan assets.
The contents of this article are for general informational purposes only and Risk Strategies Company makes no representation or warranty of any kind, express or implied, regarding the accuracy or completeness of any information contained herein. Any recommendations contained herein are intended to provide insight based on currently available information for consideration and should be vetted against applicable legal and business needs before application to a specific client.